Unique Ingredient Identifier 22ADO53M6F is listed as a ingredient substance
| RN | 7558-79-4 |
| EC | 231-448-7 |
| NCIT | C66546 |
| RXCUI | 314838 |
| PUBCHEM | 24203 |
| MF | 2Na.HO4P |
| INCHI KEY | BNIILDVGGAEEIG-UHFFFAOYSA-L |
| SMILES | [Na+].[Na+].OP([O-])([O-])=O |
UNII 22ADO53M6F SODIUM PHOSPHATE, DIBASIC, ANHYDROUS is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| BUCCAL | FILM | 0.35 MG |
| IM - IV | INJECTABLE | 1.75 % |
| IM - IV | INJECTION | 13.92 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION | 13.92 % |
| INTRA-ARTERIAL | SUSPENSION, INJECTION | 1.42 mg/1mL |
| INTRA-ARTICULAR | INJECTABLE | 0.71 % |
| INTRALESIONAL | INJECTABLE | 0.71 % |
| INTRALESIONAL | SUSPENSION, INJECTION | 1.42 mg/1mL |
| INTRAMUSCULAR | INJECTABLE | 0.71 % |
| INTRAMUSCULAR | INJECTABLE | 0.7 mg/1mL |
| INTRAMUSCULAR | INJECTION | 27.8 % |
| INTRAMUSCULAR | INJECTION, SUSPENSION, EXTENDED RELEASE | 0.2 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | NA |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.03 % |
| INTRAMUSCULAR | SUSPENSION, INJECTION | 1.42 mg/1mL |
| INTRAOCULAR | INSERT | 2.88 % |
| INTRA-SYNOVIAL | SUSPENSION, INJECTION | 1.42 mg/1mL |
| INTRAVENOUS | INJECTABLE | 0.24 % |
| INTRAVENOUS | INJECTION | 40 MG/VIAL |
| INTRAVENOUS | INJECTION | 27.8 % |
| INTRAVENOUS | INJECTION, EMULSION | 2.8 MG/ML |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 3.25 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 1.5 % |
| INTRAVENOUS | SOLUTION | 0.048 % |
| INTRAVENOUS | SOLUTION, INJECTION | 0.01 % |
| INTRAVESICAL | SOLUTION, INJECTION | 3.83 % |
| IV(INFUSION) | INFUSION | 0.01 % |
| IV(INFUSION) | INJECTABLE | 0.012 % |
| IV(INFUSION) | INJECTION | 4 % |
| IV(INFUSION) | LIQUID | 0.476 MG/ML |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 13.92 % |
| IV(INFUSION) | SOLUTION, INJECTION | 0.012 % |
| NASAL | SOLUTION | 0.5 % |
| NASAL | SPRAY | 0.011 % |
| NASAL | SPRAY, METERED | 887.76 MCG/SPRAY |
| NASAL | SPRAY, METERED | 0.5 % |
| OPHTHALMIC | SOLUTION | 5 MG/1ML |
| OPHTHALMIC | SOLUTION | 1.28 % |
| OPHTHALMIC | SOLUTION | 0.47 %W/V |
| OPHTHALMIC | SOLUTION, DROPS | 5 MG/ML |
| OPHTHALMIC | SOLUTION, DROPS | 5 mg/1mL |
| OPHTHALMIC | SOLUTION, DROPS | 1.4 % |
| OPHTHALMIC | SOLUTION, DROPS | 0.5 %W/V |
| OPHTHALMIC | SUSPENSION | 0.25 % |
| ORAL | CAPSULE | 300 MG |
| ORAL | CAPSULE, DELAYED RELEASE | 4.8 MG |
| ORAL | CAPSULE, ENTERIC COATED PELLETS | 2 MG |
| ORAL | FILM, SOLUBLE | 0.054 MG |
| ORAL | SOLUTION | 300 MG |
| ORAL | SOLUTION, SYRUP | 17.5 MG/1ML |
| ORAL | SUSPENSION | 33 MG/5ML |
| ORAL | SUSPENSION | 6.59 mg/1mL |
| ORAL | SYRUP | 3.5 MG/1ML |
| ORAL | TABLET | 96 MG |
| ORAL | TABLET, EXTENDED RELEASE | 105 MG |
| ORAL | TABLET, FILM COATED | 0.015 MG |
| ORAL | TABLET, SUSTAINED ACTION | 110 MG |
| ORAL | TABLET, UNCOATED, LOZENGE | 31 MG |
| ORAL | TABLET, UNCOATED, TROCHE | 28 MG |
| SOFT TISSUE | SUSPENSION, INJECTION | 1.42 mg/1mL |
| SUBCUTANEOUS | INJECTABLE | 0.1 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.03 % |
| SUBCUTANEOUS | SOLUTION, INJECTION | 0.012 % |
| SUBLINGUAL | FILM | 4.066 mg |
| TOPICAL | EMULSION, AEROSOL FOAM | 0.09 %W/W |
| TOPICAL | EMULSION, CREAM | 0.36 %W/W |
| TOPICAL | GEL | NA |
| TOPICAL | LOTION | NA |
| TOPICAL | OINTMENT | NA |
| TOPICAL | SOLUTION | 0.47 %W/V |
| TOPICAL | SOLUTION, DROPS | 0.45 %W/V |
| VAGINAL | CREAM, EMULSION, SUSTAINED RELEASE | 0.09 % |